论文部分内容阅读
目的探讨化疗前18F-脱氧葡萄糖(18F-FDG)标准摄取值(SUV)对晚期非小细胞肺癌(NSCLC)疗效评价及与临床因素的关系。方法 21例晚期NSCLC患者化疗前行PET-CT检查,比较不同性别、年龄、肿瘤原发灶大小、病理类型、组织分化程度、转移部位多少等对SUV的影响,并探讨原发灶SUV与化疗疗效的关系。结果肿瘤原发病灶<3cm者的SUV水平低于≥3cm组(P<0.05);转移病灶数>2处者其SUV水平明显高于≤2处者(P<0.05);肿瘤组织高分化和中分化者SUV水平明显小于低分化和未分化者(P<0.05);不同性别、年龄、病理类型间SUV水平差异无统计学意义(P>0.05)。化疗有效者治疗前SUV水平低于化疗无效者(P<0.05)。结论化疗前18F-FDG SUV水平与原发病灶大小、分化程度、转移部位多少有关,治疗前SUV低水平者更可能从化疗中获益。
Objective To investigate the efficacy of standard 18F-FDG uptake (SUV) in advanced non-small cell lung cancer (NSCLC) before chemotherapy and its relationship with clinical factors. Methods Twenty-one patients with advanced non-small cell lung cancer (NSCLC) underwent PET-CT before chemotherapy. The effects of different sex, age, size of primary tumor, pathological type, histological differentiation, metastatic sites on SUV were compared. Efficacy of the relationship. Results The SUVs in patients with primary tumors less than 3 cm were lower than those in ≥3 cm patients (P <0.05). The number of metastatic lesions> 2 patients was significantly higher than those with SUVs less than 2 (P <0.05) The level of SUV in differentiated patients was significantly lower than that in poorly differentiated and undifferentiated patients (P <0.05). There was no significant difference in SUV levels among different sexes, ages and pathological types (P> 0.05). Chemotherapy effective SUV levels before treatment was lower than chemotherapy ineffective (P <0.05). Conclusions The level of 18F-FDG SUV before chemotherapy is related to the size, differentiation and metastasis of primary tumor. The low SUV level before treatment is more likely to benefit from chemotherapy.